Spots Global Cancer Trial Database for PCA062 in pCAD-positive Tumors.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PCA062 in pCAD-positive Tumors.
Official Title: A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors
Study ID: NCT02375958
Interventions
Study Description
Brief Summary: A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Houston, Texas, United States
Novartis Investigative Site, San Antonio, Texas, United States
Novartis Investigative Site, Villejuif Cedex, , France
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Koto ku, Tokyo, Japan
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Madrid, , Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
